The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer
Open accessAbstract
Purpose: Pretreatment prostate-specific antigen (PSA) dynamics (PSA velocity and PSA doubling time) are widely advocated as useful prognostic markers in prostate cancer. We aimed to assess the published evidence for the clinical utility of PSA dynamics in this population. Methods: We conducted a systematic review of studies published before March 2007 in which a PSA dynamic (velocity or doubling time) was calculated in patients before definitive treatment, a subsequent event (such as biopsy or recurrence) was ascertained, and the association between the two was analyzed. Our principal end point was the type of analysis reported, particularly whether the predictive accuracy of a statistical model that included both absolute PSA level and a PSA dynamic was compared with that of a model that included only PSA. Results: Eighty-seven articles were eligible for analysis. The most common end points were biopsy (42 articles), and either recurrence (14 articles) or metastases or death (14 articles) after definitive therapy. Although PSA dynamics were generally found to be associated with outcome, only one article compared predictive accuracy of models with and without a PSA dynamic: this reported that PSA velocity improved prediction slightly (from 0.81 to 0.83), but was subject to verification bias. No article used decision analytic methods to examine the clinical impact of PSA dynamics. Conclusion: There is little evidence that calculation of PSA velocity or doubling time in untreated patients provides predictive information beyond that provided by absolute PSA level alone. We see no justification for the use of PSA dynamics in clinical decision making before treatment in early-stage prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease
Carter, H. B. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03480160073037 · Cited by 1,096
Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Stephenson, A. J., Scardino, P. T., Kattan, M. W., Pisansky, T. M., Slawin, K. M., Klein, E. A., Anscher, M. S., Michalski, J. M., Sandler, H. M., Lin, D. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9607 · Cited by 888
Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy
D'Amico, A. V., Chen, M.-H., Roehl, K. A., & Catalona, W. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032975 · Cited by 740
Assessment of diagnostic tests when disease verification is subject to selection bias
Begg, C. B., & Greenes, R. A. (1983) · Biometrics · doi:10.2307/2530820 · Cited by 708
Carter, H. B., Ferrucci, L., Kettermann, A., Landis, P., Wright, E. J., Epstein, J. I., Trock, B. J., & Metter, E. J. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj410 · Cited by 556
Ali, K., Gunnar, A., Jan‐Erik, D., Lilja, H. G., Pär, L., & Jonas, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22161 · Cited by 157
Self-citationProstate-Specific Antigen as Predictor of Prostate Cancer in Black Men and White Men
Whittemore, A. S., Lele, C., FRIEDMAN, G. D., Stamey, T. A., Vogelman∥, J. H., & Orentreich∥, N. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.5.354 · Cited by 99
Prostate Specific Antigen Velocity Threshold for Predicting Prostate Cancer in Young Men
Loeb, S., Roehl, K. A., Catàlona, W. J., & Nadler, R. B. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.028 · Cited by 86
Oudard, S. M., Banu, E., Scotté, F., Banu, A., Médioni, J., Beuzeboc, P., Joly, F., Ferrero, J.-M., Goldwasser, F., & Andrieu, J. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm332 · Cited by 66
Cited by
Heidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.09.046 · Cited by 1,936
Heidenreich, A., Bellmunt, J., Bolla, M., Joniau, S., Mason, M., Matveev, V., Mottet, N., Schmid, H.-P., van der Kwast, T., Wiegel, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2010.10.039 · Cited by 1,492
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1192 · Cited by 1,221
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
Wolf, A. M. D., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., Brooks, D. D., Dash, C., Guessous, I., Andrews, K., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20066 · Cited by 965
Chen, K.-I., Li, B.-R., & Chen, Y.-T. (2011) · Nano Today · doi:10.1016/j.nantod.2011.02.001 · Cited by 645
Metadata
- Authors
- Vickers, A. J., Savage, C., O'Brien, M. F., & Lilja, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-20
- Volume
- 27
- Issue
- 3
- Pages
- 398-403
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2132565257
- Cited by
- 254
- References
- 12
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2008.18.1685
- The paper
- Vickers, A. J., Savage, C., O'Brien, M. F., & Lilja, H. (2009). Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.18.1685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.